CIPH Ciphergen Biosystems (MM)

Promising Results for Prediction of Prostate Cancer Recurrence Presented at American Urological Association Meeting by Johns Hopkins Scientists Markers Discovered by SELDI-TOF-MS Potentially Useful for Assessing Risk of Recurrence in Prostate Cancer FREMONT, Calif., May 25 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) today announced that Dr. Daniel W. Chan and Dr. Zhen Zhang, of the Johns Hopkins Medical School in Baltimore, MD, working in collaboration with Ciphergen scientists, presented results yesterday at the American Urological Association Meeting in San Antonio suggesting that two protein markers, in combination with PSA levels, may be useful in predicting risk of recurrence within five years of diagnosis. The study analyzed serum from 104 patients with prostate cancer, half of whom had a recurrence of their cancer within five years of surgery and half of whom did not after five years of follow-up. Ciphergen's SELDI-TOF-MS based ProteinChip(R) System and Arrays were used to analyze the serum proteomic profiles. Analysis revealed that two markers, when combined with the PSA level prior to radical prostatectomy, could more accurately predict the risk of recurrence than could PSA level alone. One of these markers has been identified and is a low-abundance molecule with a known association to PSA. Gail Page, President of Ciphergen's Diagnostics Division, stated, "Although much attention has been paid to the early detection of prostate cancer, prediction of clinical course remains problematic. These results suggest a possible method to better predict recurrence of disease and thereby offer more aggressive treatment to those with a higher likelihood of recurrence." About Ciphergen Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Centers(R) for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the potential use of the biomarkers with PSA levels described at the American Urological Association Meeting to improve the prediction of recurrence of prostate cancer disease after surgery, the diagnostic tests that Ciphergen Diagnostics is developing, the predictive diagnostic value of protein biomarkers, and the expectation that protein multi-marker tests will improve patient care. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ability to validate in larger studies the results reported at the American Urological Meeting as to the predictive ability of these biomarkers, ProteinChip technology's ability to successfully discover, validate and assay biomarkers and patterns of biomarkers that have diagnostic utility, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated May 10, 2005, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: investor relations, Sue Carruthers of Ciphergen Biosystems, Inc., +1-510-505-2297 Web site: http://www.ciphergen.com/

Copyright